CAR T cells for relapsed high-risk neuroblastoma
Part of Cancer clinical trials.
This trial is testing a new type of immunotherapy called hALK.CAR T cells for children and young adults with high-risk neuroblastoma that has come back or not responded to standard treatment. The goal is to see if these specially engineered cells can find and destroy the cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 1 to 30 years old (first patient in each dose group must be at least 6)
- Diagnosed with high-risk neuroblastoma that has come back or has not improved with standard treatments
- Tumor can be seen on scans or other tests
- Must have finished any previous cancer treatments and recovered from side effects
- Heart, kidney, liver, and other organs working well enough
- Able to perform daily activities (Lansky or Karnofsky score at least 50%)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
This trial tests a new treatment using your own immune cells (called C7R-GD2 CAR-T cells) that are trained to find and kill cancer cells. It's for children and young adults with osteosarcoma or neuroblastoma that has not gotten better with standard treatments.
This trial tests a new immune cell therapy (CAR-T) for people whose neuroblastoma or desmoplastic small round cell tumor has returned or not responded to standard treatments. The goal is to see if this therapy is safe and can help shrink or control the cancer.
This trial tests a new CAR-T cell therapy for children, teens, and young adults with acute lymphoblastic leukemia that has not responded to standard treatment. The goal is to see if the therapy can put the leukemia into remission so the patient may then have a stem cell transplant.
This trial tests a personalized CAR-T cell therapy that targets three specific markers (GD2, PSMA, and CD276) on neuroblastoma cells. It is for patients whose cancer has come back or not responded to standard treatment.
This Phase 1 study tests an experimental CAR T-cell treatment that targets GD2, with added immune-boosting and safety features, for children with relapsed or refractory neuroblastoma or osteosarcoma. It’s designed to see if the treatment is safe and can shrink these cancers when standard therapy hasn’t worked.
Hear when a new Relapsed Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.